About Phoremost
Phoremost is a Healthcare company based in Cambridge (United Kingdom) founded in 2015. Phenotypic screening platform developed to identify drug targets and pathways. Phoremost has raised $76.8 million across 6 funding rounds from investors including XtalPi, Cambridge Enterprise and Cambridge Angels. The company has 32 employees. Phoremost offers products and services including SITESEEKER Technology. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its legal entity is PHOREMOST LIMITED.
Company details
Phoremost develops a phenotypic screening platform to identify specific targetspathways. The companys proprietary Protein Interference technology (PROTEINi) is a live-cell assay system that probes for the druggable sites across the whole human genome. It has also developed Site-Seekerplatform which is a phenotypic screening platform that identifies the new targets for drug development. Its lead therapeutic program has identified drug candidates to synthetic lethal target for KRAS which is a viral oncogene homolog.
- Headquarters Cambridge, United Kingdom
- Employees 32
- SectorsHealthcare
- Website phoremost.com
- Social LinkedIn X
- Legal Name Phoremost Limited
- Date of Incorporation 01 Apr, 2014
- Jurisdiction PAMPISFORD, UNITED KINGDOM
- Annual Revenue$1.04 M (USD)13as on Mar 31, 2022
- Net Profit-$10.31 M (USD)-61as on Mar 31, 2022
- EBITDA-$12.52 M (USD)-68as on Mar 31, 2022
- Total Equity Funding$76.8M (USD)
in 6 rounds
- Latest Funding Round$12M (USD), Series B
Sep 2024
- InvestorsXtalPi
& 13 more
- Employee Count32
Products & Services of Phoremost
Phoremost offers a comprehensive portfolio of products and services, including SITESEEKER Technology.
Tool for identifying novel targets in oncology and protein degradation fields
Funding Insights of Phoremost
Phoremost has successfully raised a total of $76.8M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $12 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $76.8M
- Total Rounds 6
- Last Round Series B — $12M
- Investors Count 14
All 6 funding rounds of Phoremost with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $12M | Series B | – | Parkwalk | |
| Mar 2021 | $46M | Series B | – | BGF | |
| May 2018 | $15M | Series A | – | Amadeus Capital, Cambridge Enterprise | |
| May 2015 | $2.16M | Grant | – | – | |
| Apr 2015 | $3.8M | Seed | – | – | |
| Mar 2015 | Seed | – | – |
14 investors in total: 11 institutional and 3 angel.
Investors in Phoremost
Phoremost has secured backing from 14 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include XtalPi, Cambridge Enterprise and Cambridge Angels.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech companies are invested in by Parkwalk venture capital firm. | parkwalkadvisors.com | London, United Kingdom | ||
Early & Growth stage tech & offline focused VC firm funding companies in the UK & Ireland | bgf.co.uk | Belfast, United Kingdom | ||
| astellasventure.com | ||||
Early-stage deep technology investments are made by Amadeus Capital. | amadeuscapital.com | London, United Kingdom | ||
A venture capital firm focused on technology and innovation investments. | 5ycap.com | Shanghai, China | ||
Multiple sectors are invested in by Morningside, a VC fund. | morningside.com | Newton, United States | ||
Angel network investing in the UK | 2002 | cambridgeangels.com | Cambridge, United Kingdom | |
AI-driven crystal structure prediction for pharmaceutical development is offered. | 2014 | xtalpi.com | Cambridge, United States | |
Invests in biotech therapeutics and AI technologies through EIS funds. | 2014 | o2hventures.com | Cambridge, United Kingdom | |
Provider of intellectual property management and technology consulting services | 2006 | enterprise.cam.ac.uk | Cambridge, United Kingdom |
Investor details for Phoremost
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Phoremost
19 people are tracked at Phoremost (4 in leadership, 11 in board & advisors, 4 in team); the tracked headcount is 32.
| Name | Role | Group |
|---|---|---|
Andrew Muncey | Consultant CFO | Leadership |
Benedict Cross | CTO | Leadership |
Neil Torbett | CEO & Director | Leadership |
Charli Howes | COO | Leadership |
Jason R. Dinges | Non-Exec Director | Board & advisors |
Xiaolu Huang | Non-Exec Director | Board & advisors |
Alastair Kilgour | Non-Executive Director | Board & advisors |
Lorenz Mayr | Non-Executive Director | Board & advisors |
Chris Torrance | Founder & Chair | Board & advisors |
Catherine Beech | Non-Executive Director | Board & advisors |
Hermann Hauser | Non-Executive Director | Board & advisors |
Tim Rea | Non-Executive Director | Board & advisors |
Peter Parker | Scientific Advisor | Board & advisors |
Simon Cook | Chair, Scientific Advisory Board | Board & advisors |
Jason Imbriglio | Scientific Advisor | Board & advisors |
Christian Dillon | CSO | Team |
Jia Lu | Principal Scientist | Team |
Poonam Shah | Senior Scientist | Team |
Matthew Jones | Senior Bioinformatics Scientist II | Team |
Complete people profiles for Phoremost
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Phoremost
3 dated milestones of Phoremost across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Phoremost is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $12.0M.
Web traffic of Phoremost
The website of Phoremost (phoremost.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 18.9% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Phoremost (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Phoremost
Complete news archive for Phoremost
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Phoremost
Phoremost was founded in 2015.
Phoremost is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Phoremost is a funded company, having raised a total of $76.8M across 6 funding rounds to date.
Phoremost has 32 employees.
Annual revenue of Phoremost is $1.04M as on Mar 31, 2022.
Phoremost develops a phenotypic screening platform to identify specific targetspathways. The companys proprietary Protein Interference technology (PROTEINi) is a live-cell assay system that probes for the druggable sites across the whole human genome. It has also developed Site-Seekerplatform which is a phenotypic screening platform that identifies the new targets for drug development. Its lead therapeutic program has identified drug candidates to synthetic lethal target for KRAS which is a viral oncogene homolog.
Phoremost offers SITESEEKER Technology.
Phoremost has 14 investors. Key investors include XtalPi, Cambridge Enterprise, Cambridge Angels, Parkwalk, and BGF.
Phoremost operates through Phoremost Limited.